HomeBUSINESS
BUSINESS

Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
(May.16.2018)

Daiichi Sankyo announced on May 15 that it will expand its joint research with Canadian biotech Zymeworks in the field of oncology. In addition to a cross-licensing agreement related to bispecific antibodies sealed in 2016, Daiichi Sankyo will acquire the right to use Zymeworks’ platforms for manufacturing two more bispecific antibodies ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar